LABORATORY CORP OF AMERICA HOLDINGS Form 8-K February 24, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

February 24, 2014 (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS		
(Exact Name of Registrant as Specified in its Charter)		
Delaware	1-11353	13-3757370
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer Identification
Incorporation)	(Commission File Number)	No.)
358 South Main Street,		
Burlington, North Carolina	27215	336-229-1127
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On February 24, 2014, Laboratory Corporation of America[®] Holdings (LabCorp[®]) (NYSE: LH) the availability of Thermo Scientific ImmunoCAPTM allergy testing products from Thermo Fisher Scientific, Inc. (NYSE: TMO). Exhibits

99.1 Press Release dated February 24, 2014

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS Registrant

By: /s/ F. SAMUEL EBERTS III F. Samuel Eberts III Chief Legal Officer and Secretary

February 24, 2014